Hoth Therapeutics

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, April 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma. The anti-cancer therapeutic, which is currently in development, uses mRNA frame shifting that induces apoptosis of neoplastic mast cells.

Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers

NEW YORK, April 12, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed the formulation for HT-001, a treatment for cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR inhibitor therapies. HT-001 is expected to start its Phase 2a trial in pending approval of the IND submission.

Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial

NEW YORK, April 6, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ("Worldwide"), a full-service Contract Research Organization ("CRO") for its upcoming Phase 2a dose ranging clinical trial of HT-001 for treatment of cutaneous toxicities associated with EGFR inhibitor therapy for cancer patients. Worldwide is a midsized, full-service, global CRO founded by physicians committed to advancing medical science.

Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients

NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc.  (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent application related to the Company's method for inhibiting formation of biofilms. The notice of allowance was issued March 31, 2021 and is related to a new patent application not previously announced.

Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm

Hoth Therapeutics Inc's (NASDAQ: HOTH) development partner, Voltron Therapeutics Inc has announced positive data from its second set of preclinical animal testing of HaloVax Self-Assembling Vaccine (SAV) against COVID-19. The study investigated an updated construct to identify the best balance of immune responses to prevent the infection.

Hoth Therapeutics' Partner Voltron Therapeutics Reports Encouraging Preclinical Data From COVID-19 Vaccine Candidate

Shares of HOTH stock are blasting off on Tuesday morning after strong preclinical results from the firm's coronavirus treatment. The post HOTH Stock: The News That Has Biopharma Hoth Therapeutics Shooting Higher Today appeared first on InvestorPlace.

HOTH Stock: The News That Has Biopharma Hoth Therapeutics Shooting Higher Today

Hoth Therapeutics Inc (NASDAQ: HOTH) soars after reporting new in vitro data for its lead peptide candidate for HT-002 to treat COVID-19. Data showed that HT-002 inhibited 50% of the cytopathic effect (CPE) of the SARS-CoV-2 virus at 61.7 µM (the EC50).

Hoth Therapeutics Stock Rallies As Lead Peptide Candidate Shows Encouraging Preclinical Antiviral Activity Against COVID-19

The stock price of Hoth Therapeutics Inc (NASDAQ: HOTH) has increased by over 40% pre-market. This is why it happened.

HOTH Stock Price Increases Over 40% Pre-Market: Why It Happened

NEW YORK, March 23, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company,  today announced new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002, a novel therapeutic targeted for the treatment of COVID-19. The data was generated in collaboration with Dr. Michael Peters , Hoth Scientific Advisory Board Member and Professor of Chemical and Life Science Engineering at Virginia Commonwealth University.

Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19 Therapeutic

NEW YORK, March 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced an exclusive interview featuring Robb Knie, CEO, airing on The RedChip Money Report on the Bloomberg Television U.S. on Saturday, March 20th at 7 p.m. local time across the United States.

Hoth Therapeutics CEO, Robb Knie, Featured on the RedChip Money Report on Bloomberg TV this Saturday, March 20th

Hoth Therapeutics Inc (NASDAQ: HOTH) has entered into a Research Agreement with the University of Cincinnati Research Institute to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan. HT-006 is under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia, cystic fibrosis, chronic obstructive pulmonary disease, and ventilator-associated pneumonia.

Hoth Therapeutics Inks Research Pact For Critical Studies Of HT-006 Antibiotic

NEW YORK, March 17, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company,  today announced entering into a Research Agreement with the University of Cincinnati Research Institute ("UCRI") to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan. HT-006 is a novel antibiotic under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia (HAP), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia (VAP).

Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006

NEW YORK, March 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company,  today announced it has executed an agreement with REPROCELL Ltd., a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn's disease patients.

Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease

NEW YORK, March 10, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced the closing of its previously announced private placement of common stock and warrants to purchase shares of common stock priced at-the-market under Nasdaq rules, resulting in gross proceeds to the Company of $15.0 million. The Company sold and issued an aggregate of 7,594,937 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,594,937 shares of common stock in the private placement, at a purchase price of $1.975 per share of common stock and associated warrant.

Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

NEW YORK, March 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced that it has entered into a definitive agreement with certain institutional and accredited investors for the issuance and sale of an...

Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules

NEW YORK, March 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today provided an update on preclinical study on HT-002 for the prevention and/or treatment of Sars-CoV-2, or COVID-19. The novel peptide...

Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies

NEW YORK, March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also...

Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina State University ("NC State") to include the worldwide development and commercialization of treatments...

Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relations efforts. RedChip is the leader in investor relations, financial media, and research...

Hoth Therapeutics Retains RedChip to Increase Investor Awareness

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has filed a provisional patent application with the United States Patent and Trademark Office for the use of one of its current portfolio therapeutics to treat...

Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment

NEW YORK, Feb. 23, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for their HT-001...

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients

Hoth Therapeutics Inc (NASDAQ: HOTH) plans to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis. The company has executed an option agreement with Isoprene Pharmaceuticals to investigate the potential.

Hoth Therapeutics Plans To Test HT-003 API In Inflammatory Bowel Disorders; Shares Spike

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel...

Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)

NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member, Michael Peter, Ph.D., published a whitepaper in bioRxiv regarding COVID-19 SARS-CoV-2 titled, "Transformations, Comparisons,...

Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv

NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed an agreement with Camargo Pharmaceutical Services to facilitate the writing and submission of the Investigational New Drug application for HT-001...

News for Hoth Therapeutics Stock (HOTH)